Polyrizon is a clinical development biotech company specializing in the development of innovative nasal gels to provide preventative treatment against a wide range of biological assaults, such as viruses, including COVID-19 and influenza, as well as allergens and other airborne pathogens.
Polyrizon’s proprietary Capture and ContainTM (C&C) hydrogel platform, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and forms a thin protective shield containment barrier in the nasal cavity to prevent infection.